Facebook Instagram X-twitter Linkedin

MT-1 (10mg)

Table of Contents

  • Quickstart Highlights

MT-1 (Melanotan I, 10mg) protocols focus on this synthetic peptide analog of alpha-MSH, studied for its potential role in stimulating melanogenesis (melanin production) and supporting natural pigmentation response in the skin. MT-1 is primarily researched for tanning support and UV-response modulation. This guide outlines a subcutaneous administration approach optimized for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical dosing range: 100–500 mcg per dose (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support melanin production and natural pigmentation response
  • Schedule: Daily or near-daily injections during the loading phase
  • Dose Range: 100–500 mcg per dose
  • Cycle Use: Often used in short loading cycles followed by maintenance dosing
  • Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 100 mcg once daily to assess tolerance
  • Target: 200–500 mcg once daily or every other day
  • Frequency: Once daily (loading phase), then 1–3 times per week (maintenance)
  • Vial Duration: One 10 mg vial lasts approximately 20–100 doses, depending on usage
  • Timing: Evening dosing is often preferred; it may be used alongside controlled UV exposure
  • Mechanism of Action

MT-1 (Melanotan I) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It binds to melanocortin receptors (primarily MC1R) on melanocytes in the skin, stimulating the production of melanin.

Melanin is the pigment responsible for skin, hair, and eye coloration and plays a protective role against ultraviolet (UV) radiation. By increasing melanin synthesis, MT-1 may enhance tanning response and reduce UV sensitivity in preclinical and clinical research contexts. Unlike direct UV exposure alone, MT-1 acts by priming melanocyte activity at the receptor level.

  • Potential Benefits & Side Effects

Observations based on clinical research and peptide studies.

Potential Benefits:

  • May support increased natural skin pigmentation (tanning effect)
  • May reduce UV sensitivity in some users
  • May promote more even skin tone under controlled exposure
  • Investigated for photoprotection-related effects

Possible Side Effects:

  • Nausea or flushing (especially during early dosing)
  • Temporary appetite changes
  • Increased libido reported in some cases
  • Darkening of moles or freckles may occur
  • Not fully approved for cosmetic use in many regions; remains investigational